ArticleBMC nephrology2026
Serum pentosidine levels are associated with reduced eGFR, including in individuals with preserved renal function: a cross-sectional analysis from the Fukuoka Epidemiological Study of Atherosclerosis.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundAdvanced glycation end products, particularly pentosidine, are implicated in age-related diseases and are influenced by renal function and glycemic status. Although elevated pentosidine levels are well documented in individuals with chronic kidney disease (CKD) stage G3b or higher, their association with early reductions in estimated glomerular filtration rate (eGFR), including in individuals with preserved renal function, remains incompletely understood.
methodsWe conducted a cross-sectional analysis of 813 Japanese adults from the Fukuoka Epidemiological Study of Atherosclerosis who underwent routine health checkups. Serum pentosidine and Nε-(carboxymethyl)lysine (CML) levels were measured and analyzed in relation to eGFR categories and glycemic markers.
resultsSerum pentosidine levels were significantly associated with early reductions in eGFR, even among individuals with values including individuals with preserved renal function (P for trend < 0.01), whereas serum CML levels remained largely unchanged. In multivariable logistic regression analysis, lower eGFR category was significantly associated with elevated serum pentosidine levels (odds ratio, 1.94; 95% confidence interval, 1.40-2.70) after adjustment for covariates. In contrast, no significant association was observed between HbA1c-defined glycemic status and serum pentosidine levels. Triglycerides, high-sensitivity C-reactive protein (hs-CRP), and obesity (body mass index ≥ 25 kg/m²) were inversely associated with serum pentosidine levels.
conclusionsLower eGFR, including in individuals with preserved renal function, was associated with higher serum pentosidine levels in this general population. These findings suggest that subtle reductions in renal function, even in individuals with preserved renal function, are associated with higher serum pentosidine levels, which may reflect a combination of cumulative oxidative stress and altered renal handling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.